Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: FLT3 Gene Mutation Negative Clear all

Active, not recruiting Phase 1 Interventional

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

NCT05918692

View directory record Official record

Conditions: Acute Myeloid Leukemia
Interventions: BMF-500; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 11 more

Source: ClinicalTrials.gov public record

Updated Feb 22, 2026 · Synced May 21, 2026, 10:11 PM EDT

Recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247

View directory record Official record

Conditions: Leukemia
Interventions: Quizartinib, Placebo, Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 53
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 44 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

NCT03512197

View directory record Official record

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Midostaurin, Placebo, Chemotherapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • Portland, Oregon

Source: ClinicalTrials.gov public record

Updated Aug 20, 2023 · Synced May 21, 2026, 10:11 PM EDT

Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768

View directory record Official record

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Emavusertib, Venetoclax; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 21, 2026, 10:11 PM EDT

Recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

NCT05886049

View directory record Official record

Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Multigated Acquisition Scan, Revumenib, Transthoracic Echocardiography Test; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years

Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Orange, California • Sacramento, California • Aventura, Florida + 19 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 1Phase 2 Interventional Results available

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01892371

View directory record Official record

Conditions: FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Azacitidine, Cytarabine, Quizartinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 5, 2025 · Synced May 21, 2026, 10:11 PM EDT